# A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

> **NCT02990806** · PHASE3 · COMPLETED · sponsor: **Nichi-Iko Pharmaceutical Co., Ltd.** · enrollment: 683 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** NI-071
- **DRUG:** Remicade

## Key facts

- **NCT ID:** NCT02990806
- **Lead sponsor:** Nichi-Iko Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-19
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02990806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02990806, "A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02990806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*